Tech Unicorn IPO Venue: Hong Kong's Sector Acceptance vs US Valuation Depth

The calculus for a Chinese tech unicorn choosing its primary listing venue has shifted decisively in 2025, driven by two concurrent forces. First, the Hong Kong Stock Exchange (HKEX) has, through its Chapter 18C and Chapter 19C listing regimes, explicitly lowered the revenue bar for “specialist technology companies” and streamlined the secondary listing pathway for US-listed Chinese issuers. Second, the US Public Company Accounting Oversight Board (PCAOB) access to Chinese audit papers, while restored in late 2022 under the Holding Foreign Companies Accountable Act (HFCAA), remains a politically renewable commitment rather than a structural guarantee. The result is a bifurcated market: Hong Kong offers regulatory certainty and sector-specific acceptance — particularly for hard-tech, biotech, and AI firms — while the US (NYSE/Nasdaq) continues to provide superior valuation depth, liquidity, and a more established analyst ecosystem for consumer internet and SaaS models. This article examines the structural trade-offs across three dimensions — regulatory cost, sectoral fit, and post-IPO liquidity — using concrete data from the 2024-2025 IPO pipeline.

Regulatory Certainty vs Political Tail Risk

The primary advantage Hong Kong holds over the US for Chinese issuers is the elimination of HFCAA-related delisting risk. As of Q1 2025, 147 Chinese companies remain listed on US exchanges with a combined market capitalisation of approximately USD 1.1 trillion, according to data from the China Securities Regulatory Commission (CSRC). However, the PCAOB’s access to the audit working papers of Chinese firms, granted under a December 2022 agreement, is subject to a three-year review cycle. Should the PCAOB determine it cannot inspect or investigate Chinese audit firms fully by the end of 2025, the HFCAA’s trading ban on non-compliant issuers would be triggered. This creates a structural overhang that depresses valuation multiples for US-listed Chinese ADRs by an estimated 15-25% relative to their US-headquartered peers, according to a 2024 study by the CFA Institute.

Hong Kong, by contrast, operates under a fully reciprocal audit framework. The HKEX’s Listing Rules require that all financial statements be prepared in accordance with Hong Kong Financial Reporting Standards (HKFRS) or International Financial Reporting Standards (IFRS), and the Financial Reporting Council (FRC) of Hong Kong has direct inspection authority over all auditors practicing in the territory. For a Chinese tech unicorn, this means no audit-related delisting risk, no PCAOB inspection uncertainty, and no need to maintain dual audit files.

The cost of this certainty is the regulatory burden of a dual-primary or secondary listing. Under HKEX Chapter 19C, a US-listed Chinese issuer seeking a secondary listing in Hong Kong must have a market capitalisation of at least HKD 10 billion (approximately USD 1.28 billion) and meet one of two revenue tests: either HKD 1 billion in revenue for the most recent financial year, or HKD 500 million in revenue with a market cap of at least HKD 40 billion. For pre-revenue specialist technology companies, Chapter 18C offers an alternative path with a minimum market cap of HKD 10 billion and no revenue requirement, but with a higher sponsor due diligence bar and a mandatory cornerstone investor requirement of at least 50% of the offering.

Sector-Specific Acceptance: Where Hong Kong Leads

Hong Kong has decisively captured the listing of hard-tech and biotech companies that face sector-specific barriers in the US. The HKEX’s Chapter 18A, introduced in 2018, allows pre-revenue biotech issuers to list on the Main Board provided they have at least one core product that has passed Phase I clinical trials and a market capitalisation of at least HKD 1.5 billion. As of December 2024, 68 biotech companies had listed under Chapter 18A, raising a cumulative HKD 118 billion (approximately USD 15.1 billion), according to HKEX data. The US equivalent — listing on Nasdaq without revenue — is possible under the Nasdaq Capital Market rules for companies with a market cap of at least USD 50 million, but the US Securities and Exchange Commission (SEC) imposes significantly higher disclosure requirements for Chinese biotech firms, including detailed descriptions of PRC regulatory approvals and the risks of the VIE structure.

For AI and semiconductor companies, the advantage is even more pronounced. The US Committee on Foreign Investment in the United States (CFIUS) has, since 2022, subjected Chinese AI and chip companies to enhanced review for any acquisition or investment exceeding USD 500,000. While this does not directly block IPOs, it creates a chilling effect on US institutional investor participation. In 2024, only three Chinese AI companies listed on US exchanges, raising a combined USD 1.2 billion, compared to 12 such companies listing in Hong Kong, raising HKD 45.6 billion (approximately USD 5.85 billion). The HKEX has also amended its Chapter 18C to include “specialist technology companies” in the AI, advanced manufacturing, and new energy sectors, with a reduced revenue threshold of HKD 250 million for companies with a market cap above HKD 80 billion.

The VIE (Variable Interest Entity) structure, used by nearly all Chinese internet companies to circumvent PRC foreign ownership restrictions in value-added telecommunications services, remains a point of divergence. The SEC, under a 2021 directive from the SEC’s Division of Corporation Finance, requires all VIE-based issuers to provide prominent risk disclosures and to confirm that the VIE structure is not a mechanism to bypass PRC law. The HKEX, in its 2023 guidance note on VIE structures, took a more permissive stance, requiring only that the VIE be “necessary” for the issuer’s business and that the contractual arrangements be disclosed in the prospectus. For issuers in sectors where VIE structures are common — such as online advertising, cloud services, and education — Hong Kong offers a lower disclosure burden and reduced legal risk.

Valuation Depth: The US Advantage Remains

Despite the regulatory and sectoral advantages of Hong Kong, the US market continues to offer superior valuation depth for consumer internet and SaaS companies. The Nasdaq Composite’s price-to-earnings (P/E) ratio stood at 34.2x as of February 2025, compared to the Hang Seng Tech Index’s 22.1x, a premium of approximately 55%. This premium is not uniform across sectors: for high-growth SaaS companies with recurring revenue models, the US premium can exceed 80%, while for mature e-commerce platforms, it narrows to 20-30%.

The liquidity differential is equally stark. Average daily trading volume for US-listed Chinese ADRs in 2024 was USD 4.8 billion, compared to HKD 38.2 billion (approximately USD 4.9 billion) for the entire Hong Kong-listed tech sector. However, this aggregate figure masks concentration: the top five US-listed Chinese ADRs — Alibaba, JD.com, NetEase, Baidu, and Pinduoduo — account for 72% of total US-listed Chinese ADR volume, while the rest suffer from thin coverage. For a mid-cap unicorn with a market cap of USD 2-5 billion, the US market offers a deeper pool of specialist tech investors, including 13F-filing hedge funds and long-only tech funds, than Hong Kong.

Analyst coverage is another dimension where the US leads. As of Q1 2025, the average US-listed Chinese ADR with a market cap above USD 1 billion was covered by 18 sell-side analysts, according to Bloomberg data. The comparable figure for Hong Kong-listed tech stocks was 11 analysts. For companies in niche sectors such as enterprise SaaS or AI infrastructure, the gap widens: a US-listed firm can expect coverage from specialist firms like KeyBanc, Needham, or Piper Sandler, while a Hong Kong-listed counterpart relies on the larger but less sector-focused houses like CLSA, CICC, or Goldman Sachs (Hong Kong).

The Dual-Listing and Homecoming Trend

The response from Chinese tech unicorns has been a wave of dual listings and secondary listings that capture the best of both venues. As of February 2025, 28 Chinese companies had completed secondary listings in Hong Kong under Chapter 19C, with a further 12 having converted to dual-primary status. The dual-primary structure allows an issuer to maintain its US listing while gaining full access to the Hong Kong Stock Connect scheme, which enables mainland Chinese investors to trade Hong Kong-listed shares through the Shanghai and Shenzhen exchanges.

The Stock Connect channel has become a critical liquidity source for Hong Kong-listed tech stocks. In 2024, net southbound flows (from mainland China into Hong Kong) reached HKD 671 billion (approximately USD 86 billion), with tech stocks accounting for 38% of total flows, according to HKEX data. For a dual-primary issuer, this means access to a retail investor base of approximately 200 million mainland Chinese brokerage accounts, which trade at an average daily turnover of HKD 120 billion through the Connect schemes.

The cost of a dual listing is not trivial. The total listing expenses for a dual-primary IPO in Hong Kong, including sponsor fees, legal fees, and regulatory filing costs, typically range from HKD 80 million to HKD 150 million (USD 10-19 million), compared to USD 5-10 million for a US-only listing. The ongoing compliance costs are also higher: a dual-listed company must comply with both SEC and HKEX disclosure requirements, file separate annual reports, and maintain dual board structures.

Actionable Takeaways

1. For pre-revenue biotech or hard-tech companies, Hong Kong’s Chapter 18A or 18C provides a faster and more certain path to public listing than the US, with no PCAOB audit risk and a supportive regulatory environment for VIE structures.
2. For consumer internet or SaaS companies with proven revenue models above HKD 1 billion, a US primary listing followed by a Hong Kong secondary listing under Chapter 19C offers the optimal balance of valuation depth and regulatory redundancy.
3. The liquidity advantage of the US for mid-cap unicorns (USD 2-5 billion market cap) is real but narrowing, as Stock Connect southbound flows increasingly support Hong Kong-listed tech names.
4. Companies with significant PRC government contracts or sensitive technology should prioritise Hong Kong to avoid CFIUS scrutiny and potential US investment restrictions under the Outbound Investment Security Program.
5. The decision should be revisited every 12-18 months, as both the PCAOB access agreement and the HKEX’s Chapter 18C revenue thresholds are subject to political and regulatory change.